Drug-free macromolecular therapeutics - a new paradigm in polymeric nanomedicines

Biomaterials Science

Volumn 3, Issue 7, 2015, Pages 908-922

  Chu, Te Wei ^a   Kopeček, Jindřich ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b University of Utah   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DEATH; CELL MEMBRANES; CROSSLINKING; MACROMOLECULES; MEDICAL NANOTECHNOLOGY; NATURAL POLYMERS; OLIGONUCLEOTIDES;

B-CELL LYMPHOMA; BIO RECOGNITION; COILED COIL PEPTIDE; CYTOTOXIC COMPOUNDS; LOW MOLECULAR WEIGHT; MACROMOLECULAR THERAPEUTICS; MALIGNANT CELLS; THERAPEUTIC SYSTEMS;

FUNCTIONAL POLYMERS;

CD20 ANTIGEN; OLIGONUCLEOTIDE; POLYMER; DRUG CARRIER; MACROMOLECULE;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BIOCOMPATIBILITY; CANCER CELL; CELL ACTIVATION; CELL ADHESION; CIRCULAR DICHROISM; CROSS LINKING; DRUG TARGETING; FLUORESCENCE MOLECULAR TOMOGRAPHY; HORMONE TRANSPORT; HUMAN; HYBRIDIZATION; HYDROGEL; IMMUNOGENICITY; IMMUNOTHERAPY; MACROMOLECULE; NANOMEDICINE; NONHUMAN; NUCLEIC ACID HYBRIDIZATION; PRIORITY JOURNAL; RAJI CELL LINE; SURVIVAL TIME; TOMOGRAPHY; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG DESIGN; LYMPHOMA, B-CELL; METABOLISM; NEOPLASMS; PROCEDURES;

APOPTOSIS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; LYMPHOMA, B-CELL; MACROMOLECULAR SUBSTANCES; NANOMEDICINE; NEOPLASMS; POLYMERS;

EID: 84931459970     PISSN: 20474830     EISSN: 20474849     Source Type: Journal    
DOI: 10.1039/c4bm00442f     Document Type: Article

References (164)

1. K. Greish J. Fang T. Inutsuka A. Nagamitsu P. H. Maeda Macromolecular therapeutics Clin. Pharmacokinet. 2003 42 1089 1105
2. J. Kopeček The potential of water-soluble polymeric carriers in targeted and site-specific drug delivery J. Controlled Release 1990 11 279 290
3. J. Yang J. Kopeček Macromolecular therapeutics J. Controlled Release 2014 190 288 303
4. Y. Matsumura H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS Cancer Res. 1986 46 6387 6392
5. J. Kopeček Polymer-drug conjugates: origins, progress to date and future directions Adv. Drug Delivery Rev. 2013 65 49 59
6. L. W. Seymour et al., Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer Int. J. Oncol. 2009 34 1629 1636
7. G. Pasut F. M. Veronese PEG conjugates in clinical development or use as anticancer agents: an overview Adv. Drug Delivery Rev. 2009 61 1177 1188
8. D. P. Nowotnik E. Cvitkovic ProLindac (AP5346): a review of the development of an HPMA DACH platinum polymer therapeutic Adv. Drug Delivery Rev. 2009 61 1214 1219
9. S. D. Chipman F. B. Oldham G. Pezzoni J. W. Singer Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate Int. J. Nanomed. 2006 1 375 383
10. G. J. Weiss et al., First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies Invest. New Drugs 2013 31 986 1000
11. A. V. Yurkovetskiy R. J. Fram XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer Adv. Drug Delivery Rev. 2009 61 1193 1202
12. J. E. Zuckerman et al., Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA Proc. Natl. Acad. Sci. U. S. A. 2014 111 11449 11454
13. P. Couvreur C. Vauthier Nanotechnology: intelligent design to treat complex disease Pharm. Res. 2006 23 1417 1450
14. M. J. Vicent H. Ringsdorf R. Duncan Polymer therapeutics: clinical applications and challenges for development Adv. Drug Delivery Rev. 2009 61 1117 1120
15. C. Kellner et al., Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity J. Immunol. 2012 189 5037 5046
16. D. Destouches et al., A simple approach to cancer therapy afforded by multivalent pseudopeptides that target cell-surface nucleoproteins Cancer Res. 2011 71 3296 3305
17. Z. Zhang et al., DNA-scaffolded multivalent ligands to modulate cell function ChemBioChem 2014 15 1268 1273
18. L. L. Kiessling J. E. Gestwicki L. E. Strong Synthetic multivalent ligands in the exploration of cell-surface interactions Curr. Opin. Chem. Biol. 2000 4 696 703
19. C. R. Bollinger V. Teichgräber E. Gulbins Ceramide-enriched membrane domains Biochim. Biophys. Acta 2005 1746 284 294
20. B. Stephens T. M. Handel Chemokine receptor oligomerization and allostery Prog. Mol. Biol. Transl. Sci. 2013 115 375 420
21. K. Wu J. Liu R. N. Johnson J. Yang J. Kopeček Drug-free macromolecular therapeutics: induction of apoptosis by coiled-coil-mediated cross-linking of antigens on the cell surface Angew. Chem., Int. Ed. 2010 49 1451 1455
22. R. Siegel J. Ma Z. Zou A. Jemal Cancer statistics, 2014 CA-Cancer J. Clin. 2014 64 9 29
23. J. O. Armitage D. D. Weisenburger New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project J. Clin. Oncol. 1998 16 2780 2795
24. A. D. Zelenetz et al., Non-Hodgkin's lymphomas, version 4.2014 J. Natl. Compr. Cancer Network 2014 12 1282 1303
25. B. D. Cheson J. P. Leonard Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma N. Engl. J. Med. 2008 359 613 626
26. D. G. Maloney et al., IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma Blood 1997 90 2188 2195
27. D. G. Maloney Anti-CD20 antibody therapy for B-cell lymphomas N. Engl. J. Med. 2012 366 2008 2016
28. A. Molina A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma Annu. Rev. Med. 2008 59 237 250
29. G. Cartron et al., Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene Blood 2002 99 754 758
30. M. R. Smith Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance Oncogene 2003 22 7359
31. I. Dransfield Inhibitory FcγRIIb and CD20 internalization Blood 2014 123 606 607
32. T. Pham P. Mero J. W. Booth Dynamics of macrophage trogocytosis of rituximab-coated B cells PLoS One 2011 6 e14498
33. P. Stashenko L. M. Nadler R. Hardy S. F. Schlossman Characterization of a human B lymphocyte-specific antigen J. Immunol. 1980 125 1678 1685
34. K. C. Anderson et al., Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation Blood 1984 63 1424 1433
35. O. W. Press A. G. Farr K. I. Borroz S. K. Anderson P. J. Martin Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies Cancer Res. 1989 49 4906 4912
36. R. B. Michel M. J. Mattes Intracellular accumulation of the anti-CD20 antibody 1F5 in B-lymphoma cells Clin. Cancer Res. 2002 8 2701 2713
37. 2+ conductance found constitutively in B lymphocytes J. Cell Biol. 1993 121 1121 1132
38. T. F. Tedder P. Engel CD20: a regulator of cell-cycle progression of B lymphocytes Immunol. Today 1994 15 450 454
39. E. Janas R. Priest R. Malhotra Functional role of lipid rafts in CD20 activity? Biochem. Soc. Symp. 2005 165 175
40. P. Boross J. H. W. Leusen Mechanisms of action of CD20 antibodies Am. J. Cancer Res. 2012 2 676 690
41. M. Okroj A. Österborg A. M. Blom Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies Cancer Treat. Rev. 2013 39 632 639
42. D. Shan J. A. Ledbetter O. W. Press Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies Blood 1998 91 1644 1652
43. C. R. Kahn K. L. Baird D. B. Jarrett J. S. Flier Direct demonstration that receptor crosslinking or aggregation is important in insulin action Proc. Natl. Acad. Sci. U. S. A. 1978 75 4209 4213
44. Y. Shimizu et al., Crosslinking of the T cell-specific accessory molecules CD7 and CD28 modulates T cell adhesion J. Exp. Med. 1992 175 577 582
45. M. Fourcin et al., gp130 transducing receptor cross-linking is sufficient to induce interleukin-6 type responses J. Biol. Chem. 1996 271 11756 11760
46. L. D. Vallat Y. Park C. Li J. G. Gribben Temporal genetic program following B-cell receptor cross-linking: altered balance between proliferation and death in healthy and malignant B cells Blood 2007 109 3989 3997
47. J. P. Deans H. Li M. J. Polyak CD20-mediated apoptosis: signalling through lipid rafts Immunology 2002 107 176 182
48. J. K. Hofmeister D. Cooney K. M. Coggeshall Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis Blood Cells. Mol. Dis. 2000 26 133 143
49. T. L. Unruh et al., Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking Immunology 2005 116 223 232
50. M.-A. Ghetie et al., Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells Proc. Natl. Acad. Sci. U. S. A. 1997 94 7509 7514
51. M.-A. Ghetie H. Bright E. S. Vitetta Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin Blood 2001 97 1392 1398
52. M. J. Polyak J. P. Deans Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure Blood 2002 99 3256 3262
53. E. A. Rossi et al., Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics Cancer Res. 2008 68 8384 8392
54. R. Stein et al., Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab Blood 2006 108 2736 2744
55. C. Wang R. J. Stewart J. Kopeček Hybrid hydrogels assembled from synthetic polymers and coiled-coil protein domains Nature 1999 397 417 420
56. J. Kopeček Hydrogel biomaterials: a smart future? Biomaterials 2007 28 5185 5192
57. J. Kopeček J. Yang Smart self-assembled hybrid hydrogel biomaterials Angew. Chem., Int. Ed. 2012 51 7396 7417
58. J. Yang C. Xu C. Wang J. Kopeček Refolding hydrogels self-assembled from N-(2-hydroxypropyl)methacrylamide graft copolymers by antiparallel coiled-coil formation Biomacromolecules 2006 7 1187 1195
59. J. Yang K. Wu Č. Koňák J. Kopeček Dynamic light scattering study of self-assembly of HPMA hybrid graft copolymers Biomacromolecules 2008 9 510 517
60. S. Lv Y. Cao H. Li Tandem modular protein-based hydrogels constructed using a novel two-component approach Langmuir 2012 28 2269 2274
61. J. Kopeček Soluble biomedical polymers Polim. Med. 1997 7 191 221
62. J. Kopeček Controlled biodegradability of polymers - a key to drug delivery systems Biomaterials 1984 5 19 25
63. P. A. Vasey et al., Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents - drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee Clin. Cancer Res. 1999 5 83 94
64. J. Kopeček P. Kopečková HPMA copolymers: origins, early developments, present, and future Adv. Drug Delivery Rev. 2010 62 122 149
65. K. Ulbrich V. Šubr Structural and chemical aspects of HPMA copolymers as drug carriers Adv. Drug Delivery Rev. 2010 62 150 166
66. D. A. D. Parry R. D. B. Fraser J. M. Squire Fifty years of coiled-coils and alpha-helical bundles: a close relationship between sequence and structure J. Struct. Biol. 2008 163 258 269
67. D. N. Woolfson The design of coiled-coil structures and assemblies Adv. Protein Chem. 2005 70 79 112
68. M. G. Oakley J. J. Hollenbeck The design of antiparallel coiled coils Curr. Opin. Struct. Biol. 2001 11 450 457
69. Y. B. Yu Coiled-coils: stability, specificity, and drug delivery potential Adv. Drug Delivery Rev. 2002 54 1113 1129
70. M. Pechar et al., Coiled coil peptides as universal linkers for the attachment of recombinant proteins to polymer therapeutics Biomacromolecules 2011 12 3645 3655
71. M. Pechar et al., Coiled coil peptides and polymer-peptide conjugates: synthesis, self-assembly, characterization and potential in drug delivery systems Biomacromolecules 2014 15 2590 2599
72. K. Wu J. Yang J. Liu J. Kopeček Coiled-coil based drug-free macromolecular therapeutics: in vivo efficacy J. Controlled Release 2012 157 126 131
73. O. W. Press et al., Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas Blood 1987 69 584 591
74. R. Zhang J. Yang T.-W. Chu J. M. Hartley J. Kopeček Multimodality imaging of coiled-coil mediated self-assembly in a "drug free" therapeutic system Adv. Healthcare Mat. 2015 10.1002/adhm.201400679
75. M.-A. Ghetie et al., Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice Int. J. Cancer 1990 45 481 485
76. G. L. Griffiths et al., Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate Clin. Cancer Res. 2003 9 6567 6571
77. G. Goodman-Snitkoff et al., Defining minimal requirements for antibody production to peptide antigens Vaccine 1990 8 257 262
78. B. Říhová J. Kopeček K. Ulbrich V. Chytrý Immunogenicity of N-(2-hydroxypropyl)methacrylamide copolymers Makromol. Chem. 1985 Suppl. 9 13 24
79. P. A. O'Hern Immunogenicity of peptides having pre-determined alpha-helical and alpha-alpha fold topologies Mol. Immunol. 1991 28 1047 1053
80. K. Lövgren M. Larsson Conjugation of synthetic peptides to carrier iscoms: factors affecting the immunogenicity of the conjugate J. Immunol. Methods 1994 173 237 243
81. M. A. Dobrovolskaia S. E. McNeil Immunological properties of engineered nanomaterials Nat. Nanotechnol. 2007 2 469 478
82. J. S. Rudra P. K. Tripathi D. A. Hildeman J. P. Jung J. H. Collier Immune responses to coiled coil supramolecular biomaterials Biomaterials 2010 31 8475 8483
83. H. Gras-Masse et al., Influence of helical organization on immunogenicity and antigenicity of synthetic peptides Mol. Immunol. 1988 25 673 678
84. S. M. Lu R. S. Hodges A de novo designed template for generating conformation-specific antibodies that recognize alpha-helices in proteins J. Biol. Chem. 2002 277 23515 23524
85. M. Kverka et al., Immunogenicity of coiled-coil based drug-free macromolecular therapeutics Biomaterials 2014 35 5886 5896
86. B. Říhová V. Větvička J. Strohalm K. Ulbrich J. Kopeček Action of polymeric prodrugs based on N-(2-hydroxypropyl)methacrylamide copolymers. I. Suppression of the antibody response and proliferation of mouse splenocytes in vitro J. Controlled Release 1989 9 21 32
87. B. Říhová M. Kovář Immunogenicity and immunomodulatory properties of HPMA-based polymers Adv. Drug Delivery Rev. 2010 62 184 191
88. B. Říhová Biocompatibility of biomaterials: hemocompatibility, immunocompatiblity and biocompatibility of solid polymeric materials and soluble targetable polymeric carriers Adv. Drug Delivery Rev. 1996 21 157 176
89. T. A. Johnson O. W. Press Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience Ann. Hematol. 2000 79 175 182
90. S. Cang N. Mukhi K. Wang D. Liu Novel CD20 monoclonal antibodies for lymphoma therapy J. Hematol. Oncol. 2012 5 64
91. M. Pechar P. Kopečková L. Joss J. Kopeček Associative diblock copolymers of poly(ethylene glycol) and coiled-coil peptides Macromol. Biosci. 2002 2 199 206
92. N. C. Seeman Nucleic acid junctions and lattices J. Theor. Biol. 1982 99 237 247
93. N. C. Seeman DNA in a material world Nature 2003 421 427 431
94. Z.-G. Wang B. Ding DNA-based self-assembly for functional nanomaterials Adv. Mater. 2013 25 3905 3914
95. J. Li C. Fan H. Pei J. Shi Q. Huang Smart drug delivery nanocarriers with self-assembled DNA nanostructures Adv. Mater. 2013 25 4386 4396
96. S. Nagahara T. Matsuda Hydrogel formation via hybridization of oligonucleotides derivatized in water-soluble vinyl polymers Polym. Gels Network 1996 4 111 127
97. K. Ding F. E. Alemdaroglu M. Börsch R. Berger A. Herrmann Engineering the structural properties of DNA block copolymer micelles by molecular recognition Angew. Chem., Int. Ed. 2007 46 1172 1175
98. P. Pan et al., Thermoresponsive micellization and micellar stability of poly(N-isopropylacrylamide)-b-DNA diblock and miktoarm star polymers Langmuir 2012 28 14347 14356
99. P. E. Nielsen DNA analogues with nonphosphodiester backbones Annu. Rev. Biophys. Biomol. Struct. 1995 24 167 183
100. T.-W. Chu J. Yang R. Zhang M. Sima J. Kopeček Cell surface self-assembly of hybrid nanoconjugates via oligonucleotide hybridization induces apoptosis ACS Nano 2014 8 719 730
101. J. Summerton D. Weller Morpholino antisense oligomers: design, preparation, and properties Antisense Nucleic Acid Drug Dev. 1997 7 187 195
102. J. E. Summerton Morpholino, siRNA, and S-DNA compared: impact of structure and mechanism of action on off-target effects and sequence specificity Curr. Top. Med. Chem. 2007 7 651 660
103. D. Stein E. Foster S. B. Huang D. Weller J. Summerton A specificity comparison of four antisense types: morpholino, 2′-O-methyl RNA, DNA, and phosphorothioate DNA Antisense Nucleic Acid Drug Dev. 1997 7 151 157
104. P. L. Iversen Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation Curr. Opin. Mol. Ther. 2001 3 235 238
105. A. Amantana P. L. Iversen Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers Curr. Opin. Pharmacol. 2005 5 550 555
106. T.-W. Chu et al., A two-step pretargeted nanotherapy for CD20 crosslinking may achieve superior anti-lymphoma efficacy to rituximab 2015
107. T.-W. Chu K. M. Kosak P. J. Shami J. Kopeček Drug-free macromolecular therapeutics induce apoptosis of patient chronic lymphocytic leukemia cells Drug Delivery Transl. Res. 2014 4 389 394
108. G. Méhes Chromosome abnormalities with prognostic impact in B-cell chronic lymphocytic leukemia Pathol. Oncol. Res. 2005 11 205 210
109. L. E. van der Kolk et al., CD20-induced B cell death can bypass mitochondria and caspase activation Leukemia 2002 16 1735 1744
110. J. C. Byrd J. J. Jones J. A. Woyach A. J. Johnson J. M. Flynn Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician J. Clin. Oncol. 2014 32 3039 3047
111. N. Zhang L. A. Khawli P. Hu A. L. Epstein Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas Clin. Cancer Res. 2005 11 5971 5980
112. J. Popov et al., Multivalent rituximab lipid nanoparticles as improved lymphoma therapies: indirect mechanisms of action and in vivo activity Nanomed. 2011 6 1575 1591
113. R. N. Johnson P. Kopečková J. Kopeček Synthesis and evaluation of multivalent branched HPMA copolymer-Fab′ conjugates targeted to the B-cell antigen CD20 Bioconjugate Chem. 2009 20 129 137
114. R. N. Johnson P. Kopečková J. Kopeček Biological activity of anti-CD20 multivalent HPMA copolymer-Fab' conjugates Biomacromolecules 2012 13 727 735
115. T.-W. Chu J. Yang J. Kopeček Anti-CD20 multivalent HPMA copolymer-Fab' conjugates for the direct induction of apoptosis Biomaterials 2012 33 7174 7181
116. S. R. Aluri et al., A hybrid protein-polymer nanoworm potentiates apoptosis better than a monoclonal antibody ACS Nano 2014 8 2064 2076
117. P. Parekh et al., Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer Biomaterials 2013 34 8909 8917
118. G. Mahlknecht et al., Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth Proc. Natl. Acad. Sci. U. S. A. 2013 110 8170 8175
119. R. Pola et al., Polymer therapeutics with a coiled coil motif targeted against murine bcl1 leukemia Biomacromolecules 2013 14 881 889
120. B. Apostolovic S. P. Deacon R. Duncan H. A. Klok Hybrid polymer therapeutics incorporating bioresponsive, coiled coil peptide linkers Biomacromolecules 2010 11 1187 1195
121. B. Apostolovic S. P. Deacon R. Duncan H. A. Klok Cell uptake and trafficking behavior of non-covalent, coiled-coil based polymer-drug conjugates Macromol. Rapid Commun. 2011 32 11 18
122. D. A. Goodwin C. F. Meares Advances in pretargeting biotechnology Biotechnol. Adv. 2001 19 435 450
123. R. M. Sharkey et al., Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods Clin. Cancer Res. 2005 11 7109s 7121s
124. G. Liu et al., Tumor pretargeting in mice using (99m)Tc-labeled morpholino, a DNA analog J. Nucl. Med. 2002 43 384 391
125. G. Liu et al., Successful radiotherapy of tumor in pretargeted mice by 188Re-radiolabeled phosphorodiamidate morpholino oligomer, a synthetic DNA analogue Clin. Cancer Res. 2006 12 4958 4964
126. J. J. Mulvey et al., Self-assembly of carbon nanotubes and antibodies on tumours for targeted, amplified delivery Nat. Nanotechnol. 2013 8 763 771
127. J. Gunn S. I. Park O. Veiseh O. W. Press M. Zhang A pretargeted nanoparticle system for tumor cell labeling Mol. BioSyst. 2011 7 742 748
128. C. Chittasupho Multivalent ligand: design principle for targeted therapeutic delivery approach Ther. Delivery 2012 3 1171 1187
129. P. I. Kitov D. R. Bundle On the nature of the multivalency effect: thermodynamic model J. Am. Chem. Soc. 2003 125 16271 16284
130. H. Pan J. Yang P. Kopečková J. Kopeček Backbone degradable multiblock N-(2-hydroxypropyl)methacrylamide copolymer conjugates via reversible addition-fragmentation chain transfer polymerization and thiol-ene coupling reaction Biomacromolecules 2011 12 247 252
131. J. Yang K. Luo H. Pan P. Kopečková J. Kopeček Synthesis of biodegradable multiblock copolymers by click coupling of RAFT-generated heterotelechelic polyHPMA conjugates React. Funct. Polym. 2011 71 294 302
132. K. Luo J. Yang P. Kopečková J. Kopeček Biodegradable multiblock poly[N-(2-hydroxypropyl)methacrylamide] via reversible addition-fragmentation chain transfer polymerization and click chemistry Macromolecules 2011 44 2481 2488
133. R. Zhang J. Yang M. Sima Y. Zhou J. Kopeček Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates Proc. Natl. Acad. Sci. U. S. A. 2014 111 12181 12186
134. T. A. Davis D. K. Czerwinski R. Levy Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression Clin. Cancer Res. 1999 5 611 615
135. P.-C. Tsai F. J. Hernandez-Ilizaliturri N. Bangia S. H. Olejniczak M. S. Czuczman Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma Clin. Cancer Res. 2012 18 1039 1050
136. L. E. van der Kolk A. J. Grillo-López J. W. Baars C. E. Hack M. H. van Oers Complement activation plays a key role in the side-effects of rituximab treatment Br. J. Haematol. 2001 115 807 811
137. R. Ponce Adverse consequences of immunostimulation J. Immunotoxicol. 2008 5 33 41
138. L. C. Lands New therapies, new concerns: rituximab-associated lung injury Pediatr. Nephrol. 2010 25 1001 1003
139. M.-C. Chaumais et al., Fatal pulmonary fibrosis after rituximab administration Pediatr. Nephrol. 2009 24 1753 1755
140. E. Mössner et al., Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity Blood 2010 115 4393 4402
141. S. Herter et al., Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models Mol. Cancer Ther. 2013 12 2031 2042
142. H. Ding W. M. Prodinger J. Kopeček Identification of CD21-binding peptides with phage display and investigation of binding properties of HPMA copolymer-peptide conjugates Bioconjugate Chem. 2006 17 514 523
143. H. Ding W. M. Prodinger J. Kopeček Two-step fluorescence screening of CD21-binding peptides with one-bead one-compound library and investigation of binding properties of N-(2-hydroxypropyl)methacrylamide copolymer-peptide conjugates Biomacromolecules 2006 7 3037 3046
144. A. David P. Kopečková A. Rubinstein J. Kopeček Enhanced biorecognition and internalization of HPMA copolymers containing multiple or multivalent carbohydrate side-chains by human hepatocarcinoma cells Bioconjugate Chem. 2001 12 890 899
145. A. David P. Kopečková T. Minko A. Rubinstein J. Kopeček Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells Eur. J. Cancer 2004 40 148 157
146. P. R. Mallikaratchy et al., A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia Nucleic Acids Res. 2011 39 2458 2469
147. J. Zhou B. Soontornworajit M. P. Snipes Y. Wang Development of a novel pretargeting system with bifunctional nucleic acid molecules Biochem. Biophys. Res. Commun. 2009 386 521 525
148. Z. Peng M. Sima M. E. Salama P. Kopečková J. Kopeček Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer J. Drug Targeting 2013 21 968 980
149. M. Rusckowski T. Qu F. Chang D. J. Hnatowich Pretargeting using peptide nucleic acid Cancer 1997 80 2699 2705
150. Y. Wang et al., Pretargeting with amplification using polymeric peptide nucleic acid Bioconjugate Chem. 2001 12 807 816
151. P. Mallikaratchy et al., A self-assembling short oligonucleotide duplex suitable for pretargeting Nucleic Acid Ther. 2013 23 289 299
152. B. Yu et al., Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells Biomaterials 2013 34 6185 6193
153. Y. Yazici Rheumatoid arthritis: When should we use rituximab to treat RA? Nat. Rev. Rheumatol. 2011 7 379 380
154. S. L. Hauser et al., B-cell depletion with rituximab in relapsing-remitting multiple sclerosis N. Engl. J. Med. 2008 358 676 688
155. V. S.-F. Chan H. H.-L. Tsang R. C.-Y. Tam L. Lu C.-S. Lau B-cell-targeted therapies in systemic lupus erythematosus Cell. Mol. Immunol. 2013 10 133 142
156. V. Ramanath R. Nistala K. Chaudhary Update on the role of rituximab in kidney diseases and transplant Expert Opin. Biol. Ther. 2012 12 223 233
157. Y.-J. Huang et al., Multivalent structure of galectin-1-nanogold complex serves as potential therapeutics for rheumatoid arthritis by enhancing receptor clustering Eur. Cell. Mater. 2012 23 170 181
158. M. H. Cho et al., A magnetic switch for the control of cell death signalling in in vitro and in vivo systems Nat. Mater. 2012 11 1038 1043
159. Z. Gu J. Yamashiro E. Kono R. E. Reiter Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism Cancer Res. 2005 65 9495 9500
160. T. Wirth E. Soeth F. Czubayko H. Juhl Inhibition of endogenous carcinoembryonic antigen (CEA) increases the apoptotic rate of colon cancer cells and inhibits metastatic tumor growth Clin. Exp. Metastasis 2002 19 155 160
161. 125I radioimmunotherapy of small-volume peritoneal carcinomatosis J. Nucl. Med. 2009 50 2033 2041
162. L. Al-Zoobi et al., Enhancement of Rituximab-induced cell death by the physical association of CD20 with CD40 molecules on the cell surface Int. Immunol. 2014 26 451 465
163. N. Kotani Y. Ishiura R. Yamashita T. Ohnishi K. Honke Fibroblast growth factor receptor 3 (FGFR3) associated with the CD20 antigen regulates the rituximab-induced proliferation inhibition in B-cell lymphoma cells J. Biol. Chem. 2012 287 37109 37118
164. M. Karlsson et al., Pharmacologically controlled protein switch for ON-OFF regulation of growth factor activity Sci. Rep. 2013 3 2716